Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | CLAD-LDAC-Ven induction therapy in AML: insights from a Phase II trial

Alex Bataller • 11 Dec 2023
ASH 2023
Acute Myeloid Leukemia Leukemia Azacitidine Cladribine Cytarabine Venetoclax

Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the findings from a Phase II trial (NCT03586609) investigating cladribine (CLAD) with low-dose cytarabine (LDAC) and venetoclax (Ven), alternated with azacytidine and Ven, for acute myeloid leukemia (AML). Patients responded well to this treatment regimen, with favorable overall survival (OS), even in patients with higher-risk RAS mutations. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alex Bataller

0:44
Unmet needs in AML: TP53 mutations and maintenance therapy
Alex Bataller • 11 Dec 2023
1:12
CPX-351 with venetoclax in R/R AML: results of a Phase Ib study
Alex Bataller • 11 Dec 2023
1:09
DEC-C plus venetoclax in HR-MDS and CMML: an analysis using different response criteria
Alex Bataller • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals